Peyronie's Disease

What Will You Need To Know About Peyronie’s Disease?


Peyronie’s disease (PD) is a localized connective tissue disorder of the penis marked by focal fibrosis leading to penile deformity, sexual dysfunction, emotional distress, and pain. 

Peyronie's Disease Definition


Prevalence of the condition ranges from 3% to 9% with most men presenting between the ages of 52 and 57.



Peyronie’s disease (PD) is thought to be due to abnormal wound healing and aberrant collagen deposition leading to the formation of fibro-collagenous plaques. 



  • The plaques themselves do not undergo a normal process of remodeling, resulting in penile curvature and deformity which often persists or progresses despite resolution of physical discomfort. 
  • Many patients with Peyronie’s disease (PD) continue to suffer from both psychological distress and negative effects on their emotional and sexual relationships with their partners.
  • Patients noting numerous issues impacting their quality of life
  • Performance anxiety, concern regarding physical appearance, painful intercourse, loss of sexual confidence, concerns regarding partner satisfaction, and concerns regarding attractiveness.
  • 54% of men experienced relationship problems and 81% emotional distress attributable to Peyronie’s disease (PD)


  • Standard of care for treatment of PD has long been surgical. This can be effective but may also have undesirable side effects, including penile shortening, glans numbness, neurovascular injury, and erectile dysfunction. 
  • Oral therapeutics
  • Extracorporeal shockwave therapy
  • Intra-lesion injection therapy (ILI). 

Intra-lesion injection (ILI) has proved the most promising and is the only alternate treatment currently recommended by the American Urological Association (AUA). ILI currently approved by the US Food and Drug Administration (FDA), carrying with it a level B recommendation according to the 2015 AUA Guideline on PD.


The Intra- Lesion Injection is now available in UAE


For more information please Contact Pharma Solutions

Tel. +97142207991

Reference: Ther Adv Urol 2018, Vol. 10(4) 139– 153

Leave a comment

Your email address will not be published. Required fields are marked *

[elfsight_whatsapp_chat id='1']